Announcement from extraordinary general meeting 2cureX AB

February 10 | 2023

Today, February 10th, 2023, the extraordinary general meeting of 2cureX AB was held. Below is a summary of the decisions that were made. All decisions were made with the required majority.

Appointment of Board of directors

The extraordinary general meeting resolved for the Board of Directors to consist of current members Povl-André Bendz, Camilla Huse Bondesson, Michael Schaefer, Ole Thastrup and new member Michel Klimkeit. With this the Board of Directors shall consist of 5 board members. The extraordinary general meeting further resolved Povl-André Bendz is re-elected as Chairman of the Board.

N.B. This English text is an unofficial translation of the Swedish original announcement from the extraordinary general meeting in 2cureX AB, and in case of any discrepancies between the Swedish text and the English translation, the Swedish text shall prevail.

For more information about 2cureX:

Fernando Andreu, Chief Executive Officer
E-mail: fa@2curex.com
Telephone: +45 2279 5399
www.2curex.com

About 2cureX

2cureX is a leader in cancer drug sensitivity testing and has developed the IndiTreat® (Individual Treatment) family of tests. Starting from a sample of the patient’s tumor, IndiTreat® creates thousands of 3D replicas (tumoroids) and predicts the tumor response to the different available drugs, providing the physician with valuable information to make the treatment decisions.

The first three IndiTreat® tests are aimed at optimizing treatment decisions in patients with metastatic colorectal cancer (IndiTreat® Start for first line of therapy, IndiTreat® Extend and Explore for third line). Additional tests are under development to cover other stages of colorectal cancer as well as other gastrointestinal cancers.

According to several reports, the total yearly expenditure in cancer-related In Vitro Diagnostic (IVD) tests exceeds 17.5Bn USD worldwide, from which 2.5 Bn USD are tests directly related to therapy decision making, with a CAGR of 12.7%. Despite this, only one third of all cancer treatments are supported by one of these tests. IndiTreat® aims at filling this gap and making Precision Oncology available to all cancer patients.

The company is listed on Nasdaq First North Growth Market in Stockholm (symbol: "2CUREX"). For more information about 2cureX visit www.2cureX.com
 
Certified Adviser: Redeye AB, +46 8 121 576 90, certifiedadviser@redeye.se

Attachments

Announcement from extraordinary general meeting 2cureX AB

Previous Next